Health and Healthcare

La Jolla Gets More Hope (LJPC, BMRN)

Money_stack_pic_5La Jolla Pharmaceutical Company (NASDAQ: LJPC) has been more than just a troubled biotech.  It has even been considered an at-risk entity by some traders after it had been down more than 90% at one point, but the company may have just gotten a much needed lifeline. 

It has signed a development and commercialization pact with BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) for its Riquent®.  This is La Jolla’s investigational drug for lupus nephritis, a candidate being evaluated in a Phase 3 clinical study for orphan disease Lupus Nephritis.  Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent.  La Jolla could receive up to $289 million in cash if everything materializes properly.

Full details of the pact are available at BioHealthInvestor.com.

Jon C. Ogg
January 6, 2009

Is Your Money Earning the Best Possible Rate? (Sponsor)

Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.

However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.

There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.